Tuesday, October 27, 2026

EQT Q3 FY12/26 Earnings Review - Distribute Rating

EQT moved to Distribute at $56.29 after Q3 revenue fell 9.6%; a 44% trailing free-cash-flow margin signals cycle risk despite lower debt and an EPS beat.

EQT $33B

Cestrian Capital Research Oct 27 2 clicks

Oct 27 GFL $20B

My Last GFL Update - Hopefully

310 Value’s Newsletter 5 clicks

Oct 27 LITE $62B

Expert Call | Lumentum Optical Chip Capacity, EML/SiPh Outlook & Industry Pricing

P Equity Research 2 clicks

From X

@ACapitalLP Oct 27

A Capital on X

@310Value You don’t like the long $CWST / short $GFL pair trade? Nothing like shorting a live take-private situation to hedge an activist margin improvement story.

@ACapitalLP Oct 27

A Capital on X

@richtrades100 Isn’t it worse now that $MGM stock is lower and $PPLI is higher? Have to issue more stock as currency…

@StableBread Oct 27 2 clicks

Fajasy on X

@babyfolio @StonkChris Havent dug in much but from what i seen and heard market seems to be real wrong om $CBRS

@ACapitalLP Oct 27 1 click

A Capital on X

@KEDM_COM These guys are also in $ZD - Czech based activist fund?

@BarbarianCap Oct 27 2 clicks

Barbarian Capital on X

Robinhood quarterly revenue rises 12% as event contracts, options offset crypto slump $HOOD https://t.co/OuqJoAA9Fy

@ParadisLabs Oct 27 1 click

Paradis on X

A lot of green in AI land today from $NBIS +11.2% to $CRDO +10.8%. Over the past few weeks, financing has been the main pressure point but it seems like we've made some solid progress this week. - $META raised $97.5B, with $60B of that coming through an ATM starting in January. - $SPCX signed a $40B deal for GPU equipment. - $AVGO set up a $63B SPV to fund custom chips for Anthropic, who also eased some fears with their S-1. Feels like the rapid de-grossing over the last few weeks has mostly run its course, however according to JPM, volumes still remain light. Interestingly, GS say that there's evidence today of "increased offense being played across the AI complex". While this is still minimal, it's a notable uptick vs. the past few weeks where risk was near zero. I wonder whether the market decides to pay attention to the upcoming hurdles, or whether it keeps riding the wall of worry higher. I personally still land on some short-term choppiness when you consider how bruised investors have gotten since July + hurdles in the next few days (hyperscaler earnings, FOMC, midterms).

@Mr_Neutral_Man Oct 27

Mr Neutral Man aka "Howard Marks of REITs” on X

Only one stock is down double digits in both the 1st and 2nd half $CHTR https://t.co/knuRdXweGS

@negligible_cap Oct 27 1 click

Negligible Capital on X

$CAKE comp sales of 15.2% YoY beating the estimate of 9.5% by 60%. Unreal

Novartis (NYSE: NVS) Stock Rating: Do Nothing After Q3 FY12/26 Earnings

Novartis grew Q3 sales 4% to $14.5bn and raised profit guidance, but pipeline failures triggered a $1.9bn impairment as net debt reached…

NVS $304B

Cestrian Capital Research Oct 27 3 clicks

AppFolio 3Q26 Business Recap: AI Agents Support Growth

AppFolio grew third-quarter revenue 19% as Realm-X AI agents gained adoption, lifting guidance to $1.122 billion to $1.127 billion.

APPF $7.6B

Speedwell Research Oct 27 5 clicks

Boeing (NYSE: BA) Stock Rating: Do Nothing After Q3 FY12/26 Earnings

Boeing posted $24.2 billion in Q3 revenue and $1.5 billion in operating cash flow, but commercial aircraft lost $697 million as production…

BA $136B

Cestrian Capital Research Oct 27 1 click

TTM Technologies: The Market Already Caught On To Peak Numbers

TTM Technologies’ record Q3 and data-center exposure drove a 27.7% stock drop as investors questioned debt-funded growth, leverage and the…

TTMI $7.7B

Nicolas Bolsinger Oct 27 1 click

Are Neoclouds Dead?

Neoclouds face tighter debt financing as AI infrastructure capex outruns cash flow, leaving cash-burning GPU providers more exposed than…

NBIS $42B

Daniel Romero Oct 27 9 clicks

Quantinuum: A Quantum Leader At A Reasonable Value

Quantinuum’s trapped-ion quantum platform supports a $2 billion 2030 revenue estimate and $135 fair value, backed by $2.1 billion cash and…

QNT $1.2B

Fundamental Options Oct 27 5 clicks

Reddit: Deep Dive Analysis

Reddit generated $805 million in Q2 2026 revenue, 95% from ads, but slowing Google search referrals expose AI-driven traffic and…

RDDT $18B

Hated Moats Oct 27 6 clicks

Qualcomm Inc. (QCOM)

Qualcomm supplies chips for on-device AI agents and data center inference, with Meta and AWS agreements expanding its role across both…

QCOM $177B

SixSigmaCapital: Navigating the Financial Markets Oct 27 5 clicks

Single Stock Spotlight #17: Gamestop (GME)

GameStop’s $6.1 billion in net cash equivalents and shift toward collectibles underpin a $30 to $40 per-share valuation thesis.

GME $13B

Hidden Rock Capital's Newsletter Oct 27 4 clicks

Monte Investments Market Brief Vol. CXXXIII

Monte Investments updates Carpenter Technology after a 25% sell-off, tracks EQT’s $12.83 billion Range Resources acquisition and assesses…

CRS $15BKRMN $5.2B

Monte Independent Investment Research Oct 27 1 click

BCO · long

Brinks CO

Brink’s $6.6 billion cash-and-stock acquisition of NCR Atleos underpins the long case, citing strategic and financial rationale.

BCO $4.7B

Value Investors Club May 8 1 click

Summary of Q4 Restaurant Conference Calls

Restaurant operators reported improving traffic, accelerating unit growth and higher advertising spend, while wage inflation ran 4-5% and…

EAT $8.8BMCD $186B

Investing 501 Mar 14

A Mexican Blue Chip Bargain

Grupo Herdez, a MXN 15.2 billion Mexican food company, pairs dominant grocery brands with McCormick, Barilla and Hormel joint ventures.

GUZOF $951M

Exploring with Alluvial Capital Mar 7

One Hour Analysis: Driven Brands Holdings ($DRVN), Road Kill or Road to Redemption?

Driven Brands’ 5,000-location auto-service network pairs strong Maintenance results with Car Wash and collision-unit fixes after DRVN fell…

DRVN $2.1B

Investing 501 Feb 25

Highlights from Darden Restaurants' Q2 '23 Conference Call

Darden Restaurants posted 2.8% same-store sales growth as Olive Garden and LongHorn outperformed a softer casual-dining market, while…

DRI $25B

Investing 501 Dec 17 1 click

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $1.9B

John Hempton's Newsletter Oct 31 1 click

A Value Trap, an Ancient Stock Pitch, a Glimpse Into The Past

Four Corners’ insider-backed asset sale cut shareholder proceeds to roughly 80% of its prior share price. A 2016 Wilh.

FCPT $2.7B

Exploring with Alluvial Capital Sep 27

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.

ALNY $21B

John Hempton's Newsletter Sep 12

Purecycle and the good money after bad decision...

PureCycle’s largest shareholder, Sylebra Capital, keeps financing its delayed, over-budget plastic-recycling plant despite covenant…

PCT $653M

John Hempton's Newsletter Aug 21 2 clicks

Value Roundup

Talen’s post-bankruptcy nuclear assets, FREIT’s $22 Kushner bid and Calithera’s failed liquidation vote illustrate unusual small-cap…

TLN $17B

Exploring with Alluvial Capital Jul 5

Tuesday, October 27, 2026

A Capital on X

A Capital on X

Fajasy on X

A Capital on X

Barbarian Capital on X

Paradis on X

Mr Neutral Man aka "Howard Marks of REITs” on X

Negligible Capital on X

Investor Letters

Publications we follow

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 73 of 272

X accounts we follow

Investor letters we follow

Sectors